This invention relates to compositions containing double-stranded
ribonucleic acid (dsRNA) in a SNALP formulation, and methods of using the
compositions to inhibit the expression of the Eg5 and Vascular
Endothelial Growth Factor (VEGF), and methods of using the compositions
to treat pathological processes mediated by Eg5 and VEGF expression, such
as cancer.